Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Miraculins, an R&D company focused on biomarker discovery, has announced a non-brokered private placement offering of up to five million units at a price of C$0.15 per unit for gross proceeds of up to C$750,000.
Subscribe to our email newsletter
Each unit will be comprised of one common share of the company and one half of one share purchase warrant. Each whole warrant will entitle the holder to purchase one share at a price of C$0.25 for a period of 12 months from the date the warrant is issued.
The net proceeds of the offering will be used for the company’s R&D program and for working capital purposes.
The offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.